Advertisement
DHR vs RGEN
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Repligen Corporation (RGEN) Stock Comparison
Key Takeaways
- Danaher Corporation (DHR) operates as a diversified healthcare conglomerate with significant exposure across diagnostics, life sciences, and biotechnology, while Repligen Corporation (RGEN) focuses primarily on bioprocessing technologies and systems for biologic drug manufacturing.
- In recent market activity, both stocks have navigated broader healthcare sector dynamics, with RGEN demonstrating relatively stronger year-to-date momentum compared to DHR in available performance data.
- DHR maintains a substantially larger market capitalization and more stable earnings profile, supported by its scale and diversified revenue streams.
- RGEN exhibits higher valuation multiples and greater sensitivity to bioprocessing demand trends, contributing to elevated volatility relative to DHR.
- Sector exposure for both centers on life sciences tools and services, though DHR benefits from additional diagnostics and broader healthcare applications that may provide relative stability.
- Market sentiment for each reflects ongoing industry focus on bioprocessing efficiency and therapeutic development, with observable differences in price consistency and growth drivers.
Introduction
This comparison examines DHR and RGEN, two stocks in the life sciences and healthcare tools sector. The analysis highlights differences in business scale, operational focus, and recent price behavior to assist traders and investors evaluating relative positioning within the current market environment. Institutional and individual market participants seeking data-driven insights into sector peers may find the review relevant for assessing trade-offs in stability, growth exposure, and momentum characteristics.
DHR Overview and Recent Performance
Danaher Corporation (DHR) develops and manufactures products for biotechnology, life sciences, and diagnostics applications. Its operations span multiple segments that support therapeutic development, disease identification, and manufacturing processes. In recent market activity, the stock has reflected steady but measured movements amid broader healthcare sector trends. Factors influencing performance include ongoing demand for diagnostic and life sciences solutions, with the company's scale contributing to more consistent price behavior compared to smaller peers. Recent weeks have shown limited volatility relative to sector averages, supported by its diversified revenue base.
RGEN Overview and Recent Performance
Repligen Corporation (RGEN) specializes in bioprocessing technologies and systems used in the production of biologic drugs, including monoclonal antibodies and cell and gene therapies. The company serves pharmaceutical and biotechnology manufacturers globally. In recent market activity, the stock has displayed comparatively stronger momentum in available year-to-date metrics. Influences on performance include shifts in bioprocessing demand and industry expansion in biologic manufacturing. Recent weeks have featured periods of outperformance relative to larger sector counterparts, accompanied by typical volatility associated with its focused business model.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds available on the platform. These bots cover thousands of different tickers and employ varied trading styles, strategies, timeframes, and performance statistics tailored to current market conditions. Only those demonstrating strong suitability and results earn placement in the trending section. Available bots feature a range of win rates, return profiles, and risk metrics that users can review for alignment with specific objectives. The resource provides an informational overview of automated trading options across diverse market environments.
Head-to-Head Comparison
Business models differ markedly: DHR offers broad diversification across diagnostics, life sciences, and biotechnology, while RGEN concentrates on bioprocessing equipment and consumables. Growth drivers for DHR include stable demand across multiple healthcare verticals; RGEN benefits from specialized expansion in biologic drug production. Recent momentum data indicate RGEN has posted higher year-to-date returns in certain periods, though this comes with greater price variability. Risk factors encompass DHR’s exposure to larger-scale integration challenges and RGEN’s sensitivity to narrower industry cycles. Sector exposure overlaps in life sciences tools, yet DHR maintains additional diagnostics reach. Market sentiment reflects these contrasts in scale and focus without uniform directional signals.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative stability, and positioning within the life sciences sector, Tickeron’s AI would currently assign a probabilistic preference toward DHR for scenarios prioritizing lower volatility and diversified exposure. RGEN may present stronger alignment in contexts emphasizing bioprocessing-specific momentum. This assessment draws from comparative performance patterns and remains subject to evolving market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a StrongBuy and RGEN is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileRGEN’s FA Score has 0 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 6 TA indicator(s) are bullish while RGEN’s TA Score has 4 bullish TA indicator(s).
- DHR’s TA Score: 6 bullish, 4 bearish.
- RGEN’s TA Score: 4 bullish, 5 bearish.
Price Growth
DHR (@Medical Specialties) experienced а +3.38% price change this week, while RGEN (@Pharmaceuticals: Other) price change was +2.42% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.19%. For the same industry, the average monthly price growth was +9.26%, and the average quarterly price growth was +1.11%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.39%. For the same industry, the average monthly price growth was +7.29%, and the average quarterly price growth was -8.66%.
Reported Earning Dates
DHR is expected to report earnings on Jul 21, 2026.
RGEN is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical Specialties (-3.19% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-2.39% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| DHR | RGEN | DHR / RGEN | |
| Capitalization | 142B | 8.17B | 1,738% |
| EBITDA | 7.08B | 176M | 4,022% |
| Gain YTD | -12.195 | -11.583 | 105% |
| P/E Ratio | 38.79 | 159.21 | 24% |
| Revenue | 24.8B | 763M | 3,250% |
| Total Cash | N/A | 785M | - |
| Total Debt | 18.5B | 688M | 2,689% |
DHR | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 29 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 80 | 90 | |
PRICE GROWTH RATING 1..100 | 52 | 47 | |
P/E GROWTH RATING 1..100 | 49 | 100 | |
SEASONALITY SCORE 1..100 | 18 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (10) in the Medical Specialties industry is significantly better than the same rating for RGEN (85) in the Biotechnology industry. This means that DHR’s stock grew significantly faster than RGEN’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
DHR's SMR Rating (80) in the Medical Specialties industry is in the same range as RGEN (90) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
RGEN's Price Growth Rating (47) in the Biotechnology industry is in the same range as DHR (52) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to DHR’s over the last 12 months.
DHR's P/E Growth Rating (49) in the Medical Specialties industry is somewhat better than the same rating for RGEN (100) in the Biotechnology industry. This means that DHR’s stock grew somewhat faster than RGEN’s over the last 12 months.
| DHR | RGEN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 50% | 1 day ago 76% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 59% | 1 day ago 77% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 72% |
| TrendMonth ODDS (%) | 1 day ago 53% | 1 day ago 71% |
| Advances ODDS (%) | 1 day ago 54% | 1 day ago 74% |
| Declines ODDS (%) | 14 days ago 61% | 21 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 56% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 49% | 1 day ago 77% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +0.56% | ||
| TMO - DHR | 77% Closely correlated | +0.28% | ||
| A - DHR | 73% Closely correlated | -0.19% | ||
| RGEN - DHR | 68% Closely correlated | +0.44% | ||
| RVTY - DHR | 65% Loosely correlated | -1.05% | ||
| MTD - DHR | 64% Loosely correlated | +0.26% | ||
More | ||||
RGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | +0.44% | ||
| DHR - RGEN | 67% Closely correlated | +0.56% | ||
| A - RGEN | 65% Loosely correlated | -0.19% | ||
| BIO - RGEN | 60% Loosely correlated | +0.50% | ||
| MTD - RGEN | 59% Loosely correlated | +0.26% | ||
| TMO - RGEN | 58% Loosely correlated | +0.28% | ||
More | ||||